Started the final stage of KEY favipiravir in patients with COVID-19

RDIF and a group of companies “Chemrar” announced the transition to the final phase multicenter randomized comparative open clinical study of favipiravir patients admitted with COVID-19. The corresponding resolution of the Ministry of health was received on 21 may.

In the final part of the study the group of participants will be expanded from 60 to 330 people. Thus, the study of the drug will cover patients in 30 centres in 9 regions.

Was previously completed phase I study (10 days therapy), with the participation of 60 patients hospitalized with coronavirus infection (COVID-19) moderate, 40 of them received therapy with favipiravir and 20 people of control group were on standard therapy. According to the results of the first phase confirmed the safety of favipiravir was not revealed any new side effects.

Efficacy of the drug was above the critical level of 80%. In 68% of patients who took favipiravir, the body temperature was normalized earlier (on day 3) than in the control group (on day 6). On average, the liberation of the body from the virus as a result of the use of favipiravir happened for 4 days, while in the group of standard therapy, the average duration is 9 days.

For the first 4 days of treatment 65% of patients of the 40 people who took favipiravir had a negative test for the coronavirus that it is 2 times more than in standard group therapy. To 10 day the number of patients with a negative test has reached 35 people out of 40.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

Murashko: the health insurance Fund fully complied with the obligations in 2019

Obligations of the Federal Fund of compulsory medical insurance in 2019, was executed in full, said the Minister of health of the Russian Federation Mikhail Murashko at the meeting of the Russian government. He added that the Fund’s revenue increased by 12% compared to 2018. “Implementation of the budget of the Federal compulsory medical insurance […]

14% tested in “in vitro” revealed specific antibodies against coronavirus

At the end of the first week of mass testing for antibodies to the new coronavirus infection of SARS-COV-2 laboratories “in vitro” was defined by the presence of immunoglobulins G 14% tested, indicating the formation of their immune response to COVID-19. In this case only the first four days of analysis for the qualitative determination […]

In Russia 8894 confirmed a new case of coronavirus

A day in Russia revealed 8894 new cases of coronavirus in 84 regions was 150 deaths. From 42.2% of new infected patients, no clinical manifestations of the disease. Just today in Russia revealed 326 448 cases of coronavirus infection. For the entire period died 3249 people have recovered 99 825 patients. In Moscow the day […]